Zoetis, Neogen deal draws antitrust concerns in Australia

Zoetis, Neogen deal draws antitrust concerns in Australia
Neogen announces sale of cleaners and disinfectants business for $130M
Neogen drops 9% as merger with 3M’s food safety business closes
2BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US6404911066
CUSIP
640491106
Sector
Healthcare
Industry
Medical Devices
Fiscal Year End
May
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
0.66
Book Value
9.66
Dividend Share
-
Dividend Yield
-
Earnings Share
-2.87
Wall Street Target Price
12.00
EPS Estimate Current Year
0.29
EPS Estimate Next Year
0.30
EPS Estimate Current Quarter
0.0533
EPS Estimate Next Quarter
0
Most Recent Quarter
-
Revenue TTM
870,561,024
Gross Profit TTM
393,576,000
EBITDA
81,262,000
Profit Margin
-69.94%
Return On Assets TTM
-0.61%
Return On Equity TTM
-25.57%
Revenue Per Share TTM
4.006
Qtly Revenue Growth YOY
-4.40%
Diluted Eps TTM
-2.87
Qtly Earnings Growth YOY
-85.60%
Trailing PE
0.00
Forward PE
16
Price Sales TTM
2.3504
Price Book MRQ
0.9505
Enterprise Value Revenue
3
Enterprise Value EBITDA
25
83.05
11.96%46.68
2.00%21.51
0.37%105.90
0.12%85.69
0.05%43.47
0.00%325.70
-6.42%67.99
-2.93%26.10
-1.34%86.07
-1.01%